Published: June 2022

This cellphone-shaped magnet (size 3.25"x6") helps publicize the new 988 Suicide & Crisis Lifeline phone number and provides access to this life-saving resource in places that are highly visible. This item comes in packs of 50.

Published: June 2022

This 4.75" by 4.75"-sized magnet helps publicize the new 988 Suicide & Crisis Lifeline phone number and provides access to this life-saving resource in places that are highly visible. This item comes in packs of 50.

Published: June 2022

This 2-sided 3.5"x2" business-sized wallet card helps publicize the 988 Suicide & Crisis Lifeline. This item comes in packs of 50.

Published: June 2022

Tarjeta de bolsillo con imagen de 988 Línea de Prevención del Suicido y Crisis This 2-sided 3.5"x2" business-sized wallet card helps publicize the 988 Suicide & Crisis Lifeline. Esta tarjeta de bolsillo de 2 caras de 3,5 "x2" ayuda a publicitar el nuevo Línea de Prevención del Suicido y Crisis. This item comes in packs of 50.

Published: June 2022

Imán Rectangular de 988 Línea de Prevención del Suicido y Crisis This cellphone-shaped magnet (size 3.25"x6") helps publicize the new 988 Suicide & Crisis Lifeline phone number and provides access to this life-saving resource in places that are highly visible. Este imán con forma de teléfono móvil (tamaño 3,25"x6") ayuda a publicitar el nuevo 988 Línea de Prevención del Suicido y Crisis y proporciona acceso a este recurso que salva vidas en lugares muy visibles. This item comes in packs of 50.

Published: June 2022

This 2-sided 3.5"x2" business-sized wallet card helps publicize the 988 Suicide & Crisis Lifeline. This item comes in packs of 50.

Published: December 2021

This resource provides information to primary care providers and practices on how to implement opioid use disorder treatment using buprenorphine. It identifies common barriers and strategies to overcome them. It documents step-by-step tactics to support buprenorphine implementation.

Published: September 2021

This guide intends to educate clinicians and other stakeholders about the harms of using more than one substance and consideration for addressing concurrent substance use (CSU) and concurrent substance use disorders (CSUD).

Published: August 2021

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.

Published: July 2021

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.